Biodegradable microspheres containing group B streptococcus vaccine: Immune response in mice

American Journal of Obstetrics and Gynecology

Volumn 185, Issue 5, 2001, Pages 1174-1179

  Hunter, Stephen K ^a,b   Andracki, Mark E ^a,b   Krieg, Arthur M ^a,b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

Adjuvants; Encapsulation; Group B Streptococcus; Mice; Vaccine

Indexed keywords

BACTERIAL POLYSACCHARIDE; IMMUNOLOGICAL ADJUVANT; MICROSPHERE; OLIGODEOXYNUCLEOTIDE; POLYGLACTIN; STREPTOCOCCUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; BLOOD SAMPLING; CONFERENCE PAPER; CONTROLLED STUDY; CPG ISLAND; DRUG DELIVERY SYSTEM; EMULSION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNOSTIMULATION; MOUSE; MOUSE STRAIN; NONHUMAN; PASSIVE IMMUNIZATION; PLACENTAL TRANSFER; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE; VACCINATION;

EID: 0035192562     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2001.117658     Document Type: Conference Paper

References (22)

1. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
2. The intestinal uptake of particles and the implications for drug and antigen delivery
3. Biodegradable microspheres: Vaccine delivery system for oral immunization
4. Enhanced secretory IgA and systemic IgG antibody response after oral immunization with biodegradable microparticles containing antigen
5. Improving the antigen delivery capacity of microparticle systems using blends of poly (DL-lactide co-glycolide) and poly (ethylene glycol)
6. Prevention of perinatal group B Streptococcal disease: A public health perspective
7. Prevention of early-onset group B Streptococcal disease in newborns
8. Revised guidelines for prevention of early-onset group B Streptococcal (GBS) infection
9. Immunization of pregnant women with a polysaccharide vaccine of group B Streptococcus
10. Response to type III polysaccharides in women whose infants have had invasive group B Streptococcal infection
11. Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus
12. Non-epitope-specific suppression of the antibody response to Haemophilus influenza type b conjugate vaccines by preimmunization with vaccine components
13. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
14. CpG motifs as immune adjuvants
15. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen
16. CpG DNA: A potent signal for growth, activation, and maturation of human dendritic cells
17. CpG DNA induces stronger immune responses with less toxicity than other adjuvants
18. The intestinal uptake of particles and the implications for drug and antigen delivery
19. Adjuvant effect of biodegradable poly(DL-lactic acid) granules capable for antigen release following intraperitoneal injection
20. Synthetic peptides entrapped in microparticles can elicit cytotoxic T-cell activity
21. Induction of mucosal and systemic immune responses by immunization with ovalbumin entrapped in poly (lactide-co-glycolide) microparticles
22. Placental transfer of maternal poliovirus antibodies in full-term and pre-term infants